Exhibit 10.1

STOCK PURCHASE AGREEMENT

THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of December 21, 2010,
is made by and among Sorrento Therapeutics, Inc., a Delaware corporation (the
“Company”), and each of the Investors listed on EXHIBIT A-1 and EXHIBIT A-2
attached hereto (each, an “Investor” and collectively, the “Investors”).

RECITALS

WHEREAS, the Investors desire to acquire from the Company, and the Company
desires to issue and sell to the Investors, in the manner and on the terms and
conditions hereinafter set forth, no less than 25,000,000 shares of common
stock, $0.0001 par value, of the Company (the “Common Stock”), and no more than
50,000,000 shares of Common Stock (collectively, the “Shares”).

NOW, THEREFORE, in consideration of these premises, the mutual covenants and
agreements herein contained and for other good and valuable consideration, the
sufficiency and receipt of which are hereby acknowledged, the Company and each
of the Investors hereby agree as follows:

SECTION I

DEFINITIONS.

The following terms when used in this Agreement have the following respective
meanings:

“1933 Act” means the Securities Act of 1933, as amended.

“1934 Act” means the Securities Exchange Act of 1934, as amended.

“Additional Closing” has the meaning set forth in Section 3.1 hereof.

“Additional Closing Date” has the meaning set forth in Section 3.1 hereof.

“Affiliate” means with respect to any Person, any (i) officer, director, partner
or holder of more than 10% of the outstanding shares or equity interests of such
Person, (ii) any relative of such Person, or (iii) any other Person which
directly or indirectly controls, is controlled by, or is under common control
with such Person. A Person will be deemed to control another Person if such
Person possesses, directly or indirectly, the power to direct or cause the
direction of the management and policies of the “Controlled” Person, whether
through ownership of voting securities, by contract, or otherwise.

“Agreement” has the meaning set forth in the preamble hereto.

--------------------------------------------------------------------------------

“Business Day” means a day other than Saturday, Sunday or statutory holiday in
the State of California and in the event that any action to be taken hereunder
falls on a day which is not a Business Day, then such action shall be taken on
the next succeeding Business Day.

“Bylaws” means the Amended and Restated Bylaws of the Company, as in effect on
the date of this Agreement.

“Certificate of Incorporation” means the Certificate of Incorporation of the
Company, as amended and restated and as on file with the Secretary of State of
the State of Delaware on the date of this Agreement.

“Closing” has the meaning set forth in Section 3.1 hereof.

“Closing Date” has the meaning set forth in Section 3.1 hereof.

“Common Stock” has the meaning set forth in the recitals hereto.

“Company” has the meaning set forth in the preamble hereto.

“Computershare” has the meaning set forth in Section 3.2(a) hereof.

“GAAP” means generally accepted accounting principles in the United States.

“Governmental Authority” means the United States, any state or municipality, the
government of any foreign country, any subdivision of any of the foregoing, or
any authority, department, commission, board, bureau, agency, court, or
instrumentality of any of the foregoing.

“Initial Closing” has the meaning set forth in Section 3.1 hereof.

“Initial Closing Date” has the meaning set forth in Section 3.1 hereof.

“Instruction Letter” has the meaning set forth in Section 3.2(a) hereof.

“Investor(s)” has the meaning set forth in the preamble hereto.

“Investor Lock-Up Agreement” means the lock-up letter agreement substantially in
the form of EXHIBIT B attached hereto.

“Knowledge of the Company” means the actual knowledge of the officers of the
Company after due and diligence inquiry of the employees or agents of the
Company reasonably believed to have knowledge of such matters.

“Lien” means any mortgage, lien, pledge, security interest, easement,
conditional sale or other title retention agreement, or other encumbrance of any
kind.

“Material Adverse Effect” means a change or effect in the condition (financial
or otherwise), properties, assets, liabilities, rights, operations or business
of the Company which change or effect, individually or in the aggregate, could
reasonably be expected to be materially adverse to such condition, properties,
assets, liabilities, rights, operations or business.

 

-2-

--------------------------------------------------------------------------------

“Person” means an individual, corporation, limited liability company,
partnership, joint venture, trust, unincorporated organization, or Governmental
Authority.

“Purchase Price” means $0.14 per Share.

“SEC” means the United States Securities and Exchange Commission.

“SEC Filings” has the meaning set forth in Section 4.2(d) hereof.

“Shares” has the meaning set forth in the recitals hereto.

“Stockholders” mean the record holders of shares of capital stock of the
Company.

SECTION II

PURCHASE AND SALE OF COMMON STOCK.

2.1 Issuance and Purchase of Common Stock.

(a) At the Initial Closing, based upon the representations, warranties,
covenants and agreements of the parties set forth in this Agreement, the Company
shall issue and sell to each Investor identified on EXHIBIT A-1 attached hereto,
and each such Investor shall purchase from the Company, that number of Shares
set forth opposite such Investor’s name on EXHIBIT A-1 attached hereto. At the
Initial Closing, the Company shall deliver to each such Investor a copy of the
Instruction Letter against payment of the purchase price set forth opposite such
Investor’s name on EXHIBIT A-1.

(b) At the Additional Closing, if applicable, based upon the representations,
warranties, covenants and agreements of the parties set forth in this Agreement,
the Company shall issue and sell to each Investor identified on EXHIBIT A-2
attached hereto, and each such Investor shall purchase from the Company, that
number of Shares set forth opposite such Investor’s name on EXHIBIT A-2 attached
hereto. At the Additional Closing, the Company shall deliver to each such
Investor a copy of the Instruction Letter against payment of the purchase price
set forth opposite such Investor’s name on EXHIBIT A-2.

2.2 Payment for Common Stock. At each Closing, for all of the Shares issued in
such Closing, each Investor participating in such Closing shall pay to the
Company, in the aggregate, the amount obtained by multiplying the Purchase Price
by the number of Shares set forth opposite such Investor’s name on EXHIBIT A-1
or EXHIBIT A-2 attached hereto, as applicable. The Investors shall pay the
purchase price for the Shares by wire transfers of immediately available funds
to an account designated in writing by the Company.

 

-3-

--------------------------------------------------------------------------------

SECTION III

THE CLOSING.

3.1 Closings. The closing of the issuance and sale of the Shares pursuant to
Section 2.1(a) hereof (the “Initial Closing”) shall take place contemporaneously
with the execution of this Agreement by the Company and the Investors
participating in such Closing (the “Initial Closing Date”) at the offices of
Paul, Hastings, Janofsky & Walker LLP, in Palo Alto, CA, or such other place as
agreed to by the Company and such Investors; provided, however, that the Initial
Closing shall occur by no later than 5 p.m. (PT) on December 31, 2010. The
closing of the issuance and sale of the Shares pursuant to Section 2.1(b)
hereof, if applicable (the “Additional Closing” and, together with the Initial
Closing, the “Closings”), shall take place contemporaneously with the execution
of a counterpart signature page to this Agreement by each of the Investors
participating in such Closing, and acceptance of such counterpart signature
page(s) by the Company (the “Additional Closing Date” and, together with the
Initial Closing Date, the “Closing Dates”) at the offices of Paul, Hastings,
Janofsky & Walker LLP, in Palo Alto, CA, or such other place as agreed to by the
Company and such Investors; provided, however, that the Additional Closing shall
occur by no later than 5 p.m. (PT) on January 14, 2011.

3.2 Deliveries by the Company. At each Closing, the Company shall deliver or
cause to be delivered to the Investors participating in such Closing the
following items (in addition to any other items required to be delivered to the
Investors pursuant to any other provision of this Agreement):

(a) a copy of an instruction letter to Computershare Trust Company, N.A., the
transfer agent for the Common Stock, or such successor transfer agent for the
Common Stock (in either event, “Computershare”), duly executed by an officer of
the Company directing Computershare to promptly issue certificates representing
the Shares being issued and sold by the Company to the Investors pursuant to
Section 2.1 hereof, duly recorded on the books of the Company in the names of
each of the Investors as set forth on EXHIBIT A-1 or EXHIBIT A-2, as applicable
(bearing a legend that such securities have not been registered under the
1933 Act or any state securities laws) and shall deliver each such letter to
Computershare (the “Instruction Letter”); and

(b) a certificate of the Secretary of State of the State of Delaware as to the
good standing of the Company dated within five Business Days prior to the
applicable Closing Date.

3.3 Deliveries by the Investors. At each Closing, each of the Investors
participating in such Closing shall deliver or cause to be delivered to the
Company (in addition to any other items required to be delivered to the Company
pursuant to any other provision of this Agreement):

(a) payment by wire transfer of immediately available funds necessary to satisfy
each Investor’s obligations to the Company under Section 2.2 hereof and to
result in payment to the Company of the applicable purchase price; and

 

-4-

--------------------------------------------------------------------------------

(b) Unless such Investor is a party to a lock-up agreement with the Company,
dated on or about September 21, 2010, a fully-executed Investor Lock-Up
Agreement.

SECTION IV REPRESENTATIONS AND WARRANTIES.

4.1 Representations and Warranties of the Company. In order to induce each of
the Investors to purchase the Shares that it is purchasing hereunder, the
Company represents and warrants to each of the Investors (i) participating in
the Initial Closing as of the Initial Closing Date, and (ii) participating in
the Additional Closing as of the Additional Closing Date (unless another time is
expressly provided for herein) as follows:

(a) Organization and Standing. The Company is duly incorporated and validly
existing under the laws of the State of Delaware, and has all requisite
corporate power and authority to own or lease its properties and assets and to
conduct its business as it is presently being conducted. As of immediately prior
to the Initial Closing, the Company did not own any equity interest, directly or
indirectly, in any other Person or business enterprise. The Company is qualified
to do business and is in good standing in each jurisdiction in which the failure
to so qualify could reasonably be expected to have a Material Adverse Effect
upon its assets, properties, financial condition, results of operations or
business. As of immediately prior to the Initial Closing, the Company had no
subsidiaries.

(b) Capitalization. As of the Initial Closing Date, the authorized capital stock
of the Company is 600,000,000 shares, consisting of (i) 500,000,000 shares of
Common Stock, of which 225,084,127 shares are issued and outstanding as of
immediately prior to the Initial Closing and 2,280,000 are reserved for issuance
pursuant to outstanding stock options and warrants, and (ii) 100,000,000 shares
of preferred stock, par value $0.0001 per share, of which no shares are issued
and outstanding as of immediately prior to the Initial Closing. The Company has
no other class or series of equity securities authorized, issued, reserved for
issuance or outstanding. Except as set forth herein, there are (x) no
outstanding options, offers, warrants, conversion rights, contracts or other
rights to subscribe for or to purchase from the Company, or agreements
obligating the Company to issue, transfer, or sell (whether formal or informal,
written or oral, firm or contingent), shares of capital stock or other
securities of the Company (whether debt, equity, or a combination thereof) or
obligating the Company to grant, extend, or enter into any such agreement and
(y) no agreements or other understandings (whether formal or informal, written
or oral, firm or contingent) which require or may require the Company to
repurchase any of its Common Stock. There are no preemptive or similar rights
with respect to the Company’s capital stock. There are no anti-dilution or price
adjustment provisions contained in any security issued by the Company (or in any
agreement providing rights to security holders). The Company is not a party to,
and, to the Knowledge of the Company, no Stockholder is a party to, any voting
agreements, voting trusts, proxies or any other agreements, instruments or
understandings with respect to the voting of any shares of the capital stock of
the Company, or any agreement with respect to the transferability, purchase or
redemption of any shares of the capital stock of the Company. The issue and sale
of the Shares to the Investors does not obligate the Company to issue any shares
of capital stock or other securities to any Person (other than the Investors)
and will not result in a right of any holder of Company securities to adjust the
exercise, conversion, exchange or reset price under such securities. The
outstanding Common Stock is all duly and validly authorized and issued, fully
paid and nonassessable.

 

-5-

--------------------------------------------------------------------------------

(c) Capacity of the Company; Authorization; Execution of Agreements. The Company
has all requisite corporate power, authority and capacity to enter into this
Agreement and to perform the transactions and obligations to be performed by it
hereunder. The execution and delivery of this Agreement by the Company, and the
performance by the Company of the transactions and obligations contemplated
hereby, including, without limitation, the issuance and delivery of the Shares
to the Investors hereunder, have been duly authorized by all requisite action on
the part of the Company. This Agreement has been duly executed and delivered by
a duly authorized officer of the Company and constitutes a valid and legally
binding agreement of the Company, enforceable in accordance with its terms,
except as enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws of the United States (both
state and federal), affecting the enforcement of creditors’ rights or remedies
in general from time to time in effect and the exercise by courts of equity
powers or their application of principles of public policy.

(d) Status of Shares. The Shares being issued and purchased hereunder, all of
which are to be issued by the Company to the Investors and paid for by the
Investors pursuant to the terms of this Agreement, are and will be, when issued,
(i) duly authorized, validly issued, fully paid and nonassessable, (ii) issued
in compliance with all applicable United States federal and state securities
laws, (iii) subject to restrictions under this Agreement, and applicable United
States federal and state securities laws, have the rights and preferences set
forth in the Certificate of Incorporation, and (iv) free and clear of all Liens
(except for any Liens imposed on such Shares, directly or indirectly, by the
Investors).

(e) Conflicts; Defaults. The execution and delivery of this Agreement by the
Company and the performance by the Company of the transactions and obligations
contemplated hereby and thereby to be performed by it do not (i) violate,
conflict with, or constitute a default under any of the terms or provisions of,
the Certificate of Incorporation, the Bylaws, or any provisions of, or result in
the acceleration of any obligation under, any contract, note, debt instrument,
security agreement or other instrument to which the Company is a party or by
which the Company, or any of its assets, is bound; (ii) result in the creation
or imposition of any Liens (except for any Liens imposed, directly or
indirectly, by the Investors) or claims upon the Company’s assets or upon any of
the shares of capital stock of the Company; (iii) constitute a violation of any
law, statute, judgment, decree, order, rule, or regulation of a Governmental
Authority applicable to the Company; or (iv) constitute an event which, after
notice or lapse of time or both, would result in any of the foregoing. The
Company is not presently in violation of its Certificate of Incorporation or
Bylaws.

(f) SEC Filings. The SEC Filings, when filed, complied in all material respects
with the requirements of Section 13 or 15(d) of the 1934 Act, as applicable, did
not, as of the dates when filed, contain an untrue statement of material fact or
omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading. The SEC Filings are all of the filings
that the Company was required to file with the SEC during the periods covered
thereby and all such filings were made on a timely basis when due. The financial
statements of the Company included in the SEC Filings complied in all material
respects with the rules and regulations of the SEC with respect thereto as in
effect at the time of filing. Such financial statements have been prepared in
accordance with GAAP applied on a consistent basis during the periods covered by
such financial statements, except as may be otherwise specified in

 

-6-

--------------------------------------------------------------------------------

such financial statements or the notes thereto, and fairly present in all
material respects the financial position of the Company as of and for the dates
thereof and for the periods indicated, and the results of operations and cash
flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments. All material agreements to
which the Company is a party or to which the property or assets of the Company
are subject and which are required to be disclosed pursuant to the 1934 Act are
included as part of or specifically identified in the SEC Filings.

(g) Material Changes. Since the date of the latest audited financial statements
included within the SEC Filings, except as disclosed in the SEC Filings,
(i) there has been no event that would reasonably be expected to result in a
Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of the business consistent with past practice
and (B) liabilities not required to be reflected in the Company’s financial
statements pursuant to GAAP as required to be disclosed in filings made with the
SEC, (iii) the Company has not altered its method of accounting or the identity
of its auditors, (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer,
director or Affiliate, except as disclosed in reports filed with the SEC
pursuant to Section 16 of the 1934 Act.

(h) Absence of Litigation. There is no action, suit, claim, proceeding, inquiry
or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the Knowledge of the
Company, threatened against the Company.

(i) Brokers, Finders, and Agents. The Company is not, directly or indirectly,
obligated to anyone acting as broker, finder or in any other similar capacity in
connection with this Agreement or the transactions contemplated hereby. No
Person has or, immediately following the consummation of the transactions
contemplated by this Agreement, will have, any right, interest or valid claim
against the Company or, as a result of any action or inaction by the Company,
the Investors, in either case for any commission, fee or other compensation as a
finder or broker in connection with the transactions contemplated by this
Agreement, nor are there any brokers’ or finders’ fees or any payments or
promises of payment of similar nature, however characterized, that have been
paid or that are or may become payable in connection with the transactions
contemplated by this Agreement, as a result of any agreement or arrangement made
by the Company.

(j) Application of Takeover Protections. There is no control share acquisition,
business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Certificate of
Incorporation or Bylaws that is or could become applicable to any of the
Investors as a result of the Investors and the Company fulfilling their
obligations or exercising their rights under this Agreement, including without
limitation, as a result of the Company’s issuance of the Shares and the
Investors’ ownership of the Shares.

(k) Absence of Businesses. The Company has not engaged in any business and the
Company has no liability or obligation of any kind or nature other than
liabilities or obligations that are disclosed in an SEC Filing or that
ordinarily and customarily relate to the maintenance of a public company.

 

-7-

--------------------------------------------------------------------------------

(l) Disclosure. All written disclosure materials provided to the Investors
regarding the Company, its business and the transactions contemplated hereby
furnished by or on behalf of the Company are true and correct in all material
respects and as otherwise contemplated in this Agreement and do not contain any
untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein not misleading. No event or
circumstance has occurred or information exists with respect to the Company or
its business, properties, operations or financial condition, which, under
applicable law, rule or regulation, requires public disclosure or announcement
by the Company, but which has not been so publicly announced or disclosed.

4.2 Representations and Warranties of the Investors. Each of the Investors
participating in the Initial Closing, and each of the Investors participating in
the Additional Closing, if any, hereby severally, but not jointly, represents
and warrants to the Company as of the Initial Closing Date or Additional Closing
Date, respectively, as follows:

(a) Investment Intent. The Shares being purchased by the Investor hereunder are
being purchased for its own account, not as a nominee or agent, and not with the
view to, or for resale in connection with, any distribution or public offering
thereof within the meaning of the 1933 Act. The Investor understands that such
Shares have not been registered under the 1933 Act by reason of their issuance
in a transaction exempt from the registration and prospectus delivery
requirements of the 1933 Act pursuant to Section 4(2) thereof and/or the
provisions of Rule 506 of Regulation D promulgated thereunder, and under the
securities laws of applicable states and agrees to deliver to the Company, if
requested by the Company, an investment letter in customary form. The Investor
further understands that the certificates representing such Shares bear a legend
substantially similar to the following and agrees that it will hold such Shares
subject thereto:

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED DIRECTLY OR
INDIRECTLY FROM THE ISSUER WITHOUT BEING REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS, AND ARE
RESTRICTED SECURITIES AS THAT TERM IS DEFINED UNDER RULE 144 PROMULGATED UNDER
THE ACT. THESE SHARES MAY NOT BE SOLD, PLEDGED, TRANSFERRED, DISTRIBUTED OR
OTHERWISE DISPOSED OF IN ANY MANNER (“TRANSFER”) UNLESS THEY ARE REGISTERED
UNDER THE ACT AND ANY APPLICABLE SECURITIES LAWS, OR UNLESS THE REQUEST FOR
TRANSFER IS ACCOMPANIED BY A FAVORABLE OPINION OF COUNSEL, REASONABLY
SATISFACTORY TO THE ISSUER, STATING THAT THE TRANSFER WILL NOT RESULT IN A
VIOLATION OF THE ACT OR ANY APPLICABLE SECURITIES LAWS.

 

-8-

--------------------------------------------------------------------------------

(b) Capacity of the Investor; Execution of Agreement. Such Investor has all
requisite power, authority and capacity to enter into this Agreement and to
perform the transactions and obligations to be performed by it hereunder. The
execution and delivery of this Agreement, and the performance by the Investor of
the transactions and obligations contemplated hereby, have been duly authorized
by all requisite corporate or individual, as the case may be, action of the
Investor. This Agreement has been duly executed and delivered by the Investor
and constitutes a valid and legally binding agreement of the Investor,
enforceable in accordance with its terms, except as enforcement thereof may be
limited by bankruptcy, insolvency, reorganization, moratorium or other similar
laws, both state and federal, affecting the enforcement of creditors’ rights or
remedies in general from time to time in effect and the exercise by courts of
equity powers or their application of principles of public policy.

(c) Accredited Investor/Qualified Institutional Buyer. The Investor is an
“accredited investor” as defined in Rule 501(a) of Regulation D promulgated
under the 1933 Act or a “qualified institutional buyer” within the meaning of
Rule 144A(a)(1) promulgated under the 1933 Act.

(d) Suitability and Sophistication. The Investor has (i) such knowledge and
experience in financial and business matters that it is capable of independently
evaluating the risks and merits of purchasing the Shares it is purchasing;
(ii) independently evaluated the risks and merits of purchasing such Shares and
has independently determined that the Shares are a suitable investment for it;
and (iii) sufficient financial resources to bear the loss of its entire
investment in such Shares. The Investor has had an opportunity to review: the
Company’s annual report on Form 10-K for the year ended December 31, 2010, the
Company’s quarterly reports on Form 10-Q for the periods ended March 31,
2010, June 30, 2010 and September 30, 2010, the Company’s current reports on
Form 8-K filed with the SEC on January 11, 2010, January 29, 2010, February 5,
2010 and April 14, 2010, and other filings made by the Company under
Section 13(a) of the 1934 Act since September 20, 2009 (the “SEC Filings”).

(e) Brokers, Finders, and Agents. The Investor is not, directly or indirectly,
obligated to anyone acting as broker, finder, or in any other similar capacity
in connection with this Agreement or the transactions contemplated hereby. No
Person has or, immediately following the consummation of the transactions
contemplated by this Agreement, will have, any right, interest or valid claim
against the Company or the Investor for any commission, fee or other
compensation as a finder or broker in connection with the transactions
contemplated by this Agreement, nor are there any brokers’ or finders’ fees or
any payments or promises of payment of similar nature, however characterized,
that have been paid or that are or may become payable in connection with the
transactions contemplated by this Agreement, as a result of any agreement or
arrangement made by the Investor.

(f) Nationality; Residence. Each Investor is a citizen of the United States of
America and a resident of, or organized within, the state set forth underneath
such Investor’s name on EXHIBIT A-1 or EXHIBIT A-2 attached to this Agreement.

(g) General Solicitation. The Investor is not purchasing the Shares as a result
of any advertisement, article, notice or other communication regarding the
Shares published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or any other general
solicitation or general advertisement.

 

-9-

--------------------------------------------------------------------------------

4.3 Rule 144. Each Investor acknowledges that the Shares it will be purchasing
must be held indefinitely unless subsequently registered under the 1933 Act or
unless an exemption from such registration is available. Each Investor
acknowledges that the Company is neither obligated, nor has the present
intention, to register the Shares for resale pursuant to a registration
statement filed with the SEC. Each of the Investors is aware of the provisions
of Rule 144 promulgated under the 1933 Act which permit limited resale of shares
purchased in a private placement subject to the satisfaction of certain
conditions, including, among other things, the provisions of Rule 144(i), which
provide additional conditions that must be satisfied by (a) an issuer with
(i) no or nominal operations; and (ii) either (A) no or nominal assets;
(B) assets consisting solely of cash and cash equivalents; or (C) assets
consisting of any amount of cash and cash equivalents and nominal other assets;
or (b) an issuer that has been at any time previously an issuer described in
(a), and each Investor is further aware that the provisions of Rule 144(i) are
applicable to the Company. The Company shall use all commercially reasonable
efforts to file all periodic and current reports of the Company with the SEC
that are necessary in order to permit the Investors to resell their Shares
pursuant to Rule 144. At the time an Investor’s Shares become eligible for
resale under the 1933 Act, upon the request of an Investor, the Company shall
use all commercially reasonable efforts to permit such Investor to resell such
Shares in a public and/or private transaction, including, without limitation, by
coordinating with the Investor and Computershare to have any restrictive legends
relating to the 1933 Act removed from such Shares; provided, however, that the
Company shall be permitted to request a legal opinion from counsel to such
Investor as to the eligibility of the Shares to be resold pursuant to Rule 144
or another exemption under the 1933 Act.

4.4 Qualified Small Business Stock. The Company and the Investors intend that
the Shares shall constitute “qualified small business stock,” as defined under
Section 1202(c) of the Internal Revenue Code of 1986, as amended.

SECTION V

MISCELLANEOUS.

5.1 Waivers and Amendments. This Agreement may be amended or modified in whole
or in part only by a writing which makes reference to this Agreement executed by
the Investors and the Company. The obligations of any party hereunder may be
waived (either generally or in a particular instance and either retroactively or
prospectively) only with the written consent of the party claimed to have given
the waiver; provided, however, that any waiver by any party of any violation of,
breach of, or default under any provision of this Agreement or any other
agreement provided for herein shall not be construed as, or constitute, a
continuing waiver of such provision, or waiver of any other violation of, breach
of or default under any other provision of this Agreement or any other agreement
provided for herein.

5.2 Entire Agreement. This Agreement (together with the Exhibits hereto) and the
other agreements and instruments expressly provided for herein, together set
forth the entire understanding of the parties hereto and supersede in their
entirety all prior contracts, agreements, arrangements, communications,
discussions, representations and warranties, whether oral or written, among the
parties with respect to the subject matter hereof.

 

-10-

--------------------------------------------------------------------------------

5.3 Governing Law. This Agreement shall in all respects be governed by and
construed in accordance with the internal substantive laws of the State of
California without giving effect to the principles of conflicts of law thereof.
Each of the parties hereto irrevocably agrees that any legal action or
proceeding arising out of or relating to this Agreement brought by any other
party or its successors or assigns shall be brought and determined in any
California state or federal court sitting in San Diego County, California (or,
if such court lacks subject matter jurisdiction, in any appropriate California
state or federal court), and each of the parties hereby irrevocably submits to
the exclusive jurisdiction of the aforesaid courts for itself and with respect
to its property, generally and unconditionally, with regard to any such action
or proceeding arising out of or relating to this Agreement and the transactions
contemplated hereby.

5.4 Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES
ITS RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING
OUT OF THIS AGREEMENT. EACH OF THE PARTIES HERETO ALSO WAIVES ANY BOND OR SURETY
OR SECURITY UPON SUCH BOND THAT MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE
OTHER PARTY. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY
AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THIS
AGREEMENT, INCLUDING, BUT NOT LIMITED TO, CONTRACT CLAIMS, TORT CLAIMS, BREACH
OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. EACH OF THE
PARTIES HERETO ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER
INTO THIS AGREEMENT. EACH OF THE PARTIES HERETO HEREBY FURTHER ACKNOWLEDGES AND
AGREES THAT EACH HAS REVIEWED OR HAD THE OPPORTUNITY TO REVIEW THIS WAIVER WITH
ITS RESPECTIVE LEGAL COUNSEL, AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS
JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH SUCH LEGAL COUNSEL. IN THE EVENT
OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY
THE COURT.

5.5 Public Announcements. Except as provided below in this Section 5.5, none of
the parties hereto shall publicly disclose the execution, delivery or contents
of this Agreement other than (i) with the prior written consent of the other
parties hereto, or (ii) as required by any applicable law (including for the
purpose of holding stockholder or stockholder meetings and proxies therefor),
the applicable rules of any stock exchange, or any Governmental Authority.
Without limiting the foregoing, the parties understand that this Agreement, and
a summary hereof, will be publicly filed by the Company with the SEC and that
the Company may issue press releases and/or public statements with respect to
this Agreement. Nothing contained herein shall prohibit the Company from making
any such disclosure if required by any applicable law or any Governmental
Authority.

5.6 Notices. Any notice, request or other communication required or permitted
hereunder shall be in writing and be deemed to have been duly given (a) when
personally delivered or sent by facsimile transmission (the receipt of which is
confirmed in writing), (b) one Business Day after being sent by a nationally
recognized overnight courier service or (c) five Business Days after being sent
by registered or certified mail, return receipt requested, postage prepaid, to
the parties at their respective addresses set forth below.

 

-11-

--------------------------------------------------------------------------------

 

If to the Company:   

Sorrento Therapeutics, Inc.

6042 Cornerstone Ct. West, Suite B

San Diego, CA 92121

Attn: Antonius Schuh, Ph.D., CEO

Facsimile: (858) 210-3759

with a courtesy copy

(not constituting notice) to:

  

Jeff Hartlin

Paul, Hastings, Janofsky & Walker LLP

1117 S. California Avenue

Palo Alto, CA 94304-1106

Facsimile: (650) 320-1904

if to Investors:   

At the addresses set forth across from each

Investor’s name on EXHIBIT A-1 or EXHIBIT A-2

attached hereto.

 

Any party by written notice to the other may

change the address or the persons to whom

notices or copies thereof shall be directed.

5.7 Counterparts; Facsimile Signatures. This Agreement may be executed in any
number of counterparts, each of which shall be deemed to be an original, and all
of which together will constitute one and the same instrument. Any facsimile,
scanned or e-mailed copy of this Agreement will be deemed an original for all
purposes and any facsimile, scanned or e-mailed copy of an original written
signature shall be deemed to have the same effect as an original written
signature.

5.8 Successors and Assigns. This Agreement shall be binding upon and shall inure
to the benefit of the parties hereto and their respective successors and
permitted assigns, except that the Company may not assign or transfer its rights
hereunder without the prior written consent of the Investors and no Investor may
assign or transfer its rights hereunder without the prior written consent of the
Company.

5.9 Third Parties. Nothing expressed or implied in this Agreement is intended,
or shall be construed, to confer upon or give any Person other than the parties
hereto and their successors and assigns any rights or remedies under or by
reason of this Agreement.

5.10 Exhibits. The Exhibits attached to this Agreement are incorporated herein
and shall be part of this Agreement for all purposes.

5.11 Expenses. Each party shall bear and pay all of the legal, accounting and
other costs and expenses incurred by it in connection with the transactions
contemplated by this Agreement.

5.12 Headings. The headings in this Agreement are solely for convenience of
reference and shall not be given any effect in the construction or
interpretation of this Agreement.

 

-12-

--------------------------------------------------------------------------------

5.13 Interpretation. Whenever the context may require, any pronoun used herein
shall include the corresponding masculine, feminine or neuter forms, and the
singular form of nouns, pronouns and verbs shall include the plural and vice
versa.

[Signature Page Follows]

 

-13-

--------------------------------------------------------------------------------

SIGNATURE PAGES TO

STOCK PURCHASE AGREEMENT

BY AND AMONG

SORRENTO THERAPEUTICS, INC. AND THE INVESTORS

IN WITNESS WHEREOF, the Company and each of the Investors have executed this
Agreement as of the date first above written.

 

COMPANY: SORRENTO THERAPEUTICS, INC. By: /s/ Antonius Schuh, Ph.D. Name:  
Antonius Schuh, Ph.D. Title:   CEO

INVESTORS: By:  

 

Name:  

 

Title:  

 

--------------------------------------------------------------------------------

EXHIBIT A-1

INITIAL CLOSING

SCHEDULE OF INVESTORS

 

            Name, Address and
State of Residence or Organization

   Number of
Shares Purchased     Purchase Price  

[                    ]

     [                     ]      [                     ] 

TOTAL

     25,714,286      $ 3,600,000.04   

 

A-1-1

--------------------------------------------------------------------------------

EXHIBIT A-2

ADDITIONAL CLOSING

SCHEDULE OF INVESTORS

 

            Name, Address and
State of Residence or Organization

   Number of
Shares Purchased      Purchase Price              

Total:

     

 

A-2-1

--------------------------------------------------------------------------------

EXHIBIT B

INVESTOR LOCK-UP AGREEMENT

Sorrento Therapeutics, Inc.

6042 Cornerstone Ct. West, Suite B

San Diego, CA 92121

Attn: Antonius Schuh, Ph.D., CEO

Ladies and Gentlemen:

Reference is made to that certain Stock Purchase Agreement, dated December 21,
2010, by and among Sorrento Therapeutics, Inc., a Delaware corporation (the
“Company”), and the investors named the therein (the “Agreement”). This Lock-Up
Letter Agreement is being delivered by the undersigned pursuant to the
Agreement. For good and valuable consideration, the undersigned hereby
irrevocably agrees that the undersigned will not, directly or indirectly,
(1) offer for sale, sell, pledge or otherwise dispose of (or enter into any
transaction or device that is designed to, or could be expected to, result in
the disposition by any person at any time in the future of) any shares of common
stock of the Company (each, a “Share”), including, any Shares that may be deemed
to be beneficially owned by the undersigned in accordance with the rules and
regulations of the United States Securities and Exchange Commission and Shares
that may be issued upon exercise of any options or warrants, or securities
convertible into or exercisable or exchangeable for Shares, (2) enter into any
swap or other derivatives transaction that transfers to another, in whole or in
part, any of the economic benefits or risks of ownership of Shares, whether any
such transaction described in clause (1) or (2) above is to be settled by
delivery of Shares or other securities, in cash or otherwise, (3) make any
demand for or exercise any right or cause to be filed a registration statement,
including any amendments thereto, with respect to the registration of any Shares
or securities convertible into or exercisable or exchangeable for Shares or any
other securities of the Company, or (4) publicly disclose the intention to do
any of the foregoing, in each case on or prior to September 21, 2011.
Notwithstanding the foregoing, this Lock-Up Letter Agreement shall automatically
terminate and the undersigned holder will be automatically released from any
transfer restrictions hereunder on the last business date that is immediately
prior to the consummation of a Change of Control. For purposes hereof, a “Change
of Control” shall mean any transaction or series of transactions involving
(i) any merger, consolidation, share exchange, business combination, issuance of
securities, direct or indirect acquisition of securities, recapitalization,
tender offer, exchange offer or other similar transaction involving the Company,
as a result of which the stockholders of the Company immediately prior to such
transaction hold, in the aggregate, less than 50% of the voting power of the
Company or the surviving entity immediately after such transaction on a
fully-diluted basis; (ii) any direct or indirect sale, lease, exchange,
transfer, license, acquisition or disposition of all or substantially all of the
business or assets (including intangible assets) of the Company; or (iii) any
liquidation or dissolution of the Company.

 

B-1

--------------------------------------------------------------------------------

In furtherance of the foregoing, the Company and its transfer agent on its
behalf are hereby authorized to decline to make any transfer of securities if
such transfer would constitute a violation or breach of this Lock-Up Letter
Agreement.

The undersigned hereby represents and warrants that the undersigned has full
power and authority to enter into this Lock-Up Letter Agreement and that, upon
request, the undersigned will execute any additional documents necessary in
connection with the enforcement hereof. Any obligations of the undersigned shall
be binding upon the heirs, personal representatives, successors and assigns of
the undersigned.

 

Yours truly,

By:                                                                 
                 

Name:                                                                 
            

Title:                                                                 
              

 

Dated: Accepted and Acknowledged: Sorrento Therapeutics, Inc.
By:                                                                       
       Name:                             
                                          Title:                            
                                             

 

B-2